The 30-day survival rate for the 147 fulminant hepatic failure patients in the study was 59% for patients randomized to the regular standard of care (SOC) and 73% for patients treated with the standard of care plus the HepatAssist bioartificial liver support system.
The study was funded by a grant from Circe Biomedical Inc., the manufacturer of the HepatAssist bioartificial liver support system.